ABP-PEG-peptide-conjugated oncolytic adenovirus therapy expressing anti-c-Met shRNA (University of Utah)

N/A

Report date: 2026/02/03 17:44:34

Base Information

Drug NameABP-PEG-peptide-conjugated oncolytic adenovirus therapy expressing anti-c-Met shRNA (University of Utah)

Drug Alias Namesmart oncolytic Ad nanocomplex (University of Utah)(ABP)-PEG-HCBP1oAd/shMet-ABP-PEG-HCBP1 complex

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNABiologics > Oncolytic virusSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) +[4]

Mechanisms of ActionImmunostimulants

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe University Of Utah

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe University Of Utah

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A